InvestorsHub Logo
Followers 24
Posts 1728
Boards Moderated 0
Alias Born 08/07/2022

Re: attilathehunt post# 431260

Monday, 09/18/2023 11:33:21 AM

Monday, September 18, 2023 11:33:21 AM

Post# of 462468
The CEO is doing...really well. Over 10 years, he has brought the company from P1 to the brink of submitting NDAs for 2 indications. And pivotal trials for 2 additional indications (Fragile X and PD) are teed up. There is not much else, IMO, that you could ask for from a biotech CEO: the company is well-funded with minimal dilution, it has progressed at pretty close to the statutorily allowed speed during a 2 year pandemic shutdown, and he has staffed the company with competent experts (some of whom are leaders in their field.) Good stuff.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News